Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game
Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.
You may also be interested in...
If the beginning of 2017 was marked by doubts around whether and how the FDA would act with respect to complex diagnostics, we enter 2018 feeling that slow-moving vessel may finally be turning.
Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.
The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.